ICU Medical (ICUI) CEO logs 250% PRSU payout and share withholding for taxes
Rhea-AI Filing Summary
ICU Medical Chairman and CEO Vivek Jain reported multiple equity award transactions. On March 8, 2026, he exercised 107,635 performance shares at $0.00 per share, acquiring the same number of common shares, which were earned at 250% of target PRSU performance after Compensation Committee certification.
That same day, 59,500 common shares were disposed of at $132.00 per share to satisfy tax obligations through share withholding, not an open-market sale. On March 7, 2026, he exercised awards covering 5,282 shares twice (derivative and non-derivative reporting), and 2,919 shares were withheld for taxes. Following these events, he also reported 152,339 common shares held indirectly through a trust.
Positive
- None.
Negative
- None.
Insights
Transactions mainly reflect equity award vesting and tax withholding, not open-market trading.
The filing shows Vivek Jain settling performance-based restricted stock units that paid out at 250% of target, indicating strong achievement of the plan’s performance goals. Shares were acquired via exercises at $0.00 exercise price, consistent with stock-based compensation mechanics.
Dispositions coded F are labeled as share withholding to cover tax liabilities, including 59,500 shares at $132.00. These are not discretionary market sales. The report also lists 152,339 shares held indirectly through a trust, clarifying total beneficial ownership after these equity award events.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Performance Shares | 107,635 | $0.00 | -- |
| Exercise | Common Stock | 107,635 | $0.00 | -- |
| Tax Withholding | Common Stock | 59,500 | $132.00 | $7.85M |
| Exercise | Common Stock | 5,282 | $0.00 | -- |
| Exercise | Common Stock | 5,282 | $0.00 | -- |
| Tax Withholding | Common Stock | 2,919 | $0.00 | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- These securities are Restricted Stock Units. Represents the settlement of performance stock units granted on 3/8/2024. Upon the certification of performance results by the Compensation Committee on 2/11/26, the PRSUs were earned at 250% of target, resulting in the acquisition of the shares reported herein. There is neither a purchase price nor an exercise price for the Restricted Stock Units. One third of the units subject to the award shall vest on each of the first, second, and third anniversaries of the grant date. These are restricted stock units that fully vest 3 years from the grant date. These Securities are Performance-based Restricted Stock Units (PRSU). There is neither a purchase price nor an exercise price for the PRSUs.
